Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05156905 · ClinicalTrials.gov registry record · Phase 1
Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
A Phase 1 study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05156905 is a Phase 1 study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 6 participants.
The verdict
NCT05156905, a Phase 1 study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety and efficacy of cirmtuzumab in combination with standard of care docetaxel in patients with metastatic castration resistant prostate cancer. Docetaxel is a taxane chemotherapy which has been shown to prolong survival in men with castration resistant prostate cancer. Cirmtuzumab is a monoclonal antibody that targets the receptor called ROR1 of the non-canonical Wnt pathway and is suspected to contribute to prostate cancer growth and progression.
Interventions
- DRUG Cirmtuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-06-16 |
| Est. Completion | 2024-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05156905
The ClinicalTrials.gov registry entry for NCT05156905 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cirmtuzumab is the first listed.
NCT05156905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05156905 about?
NCT05156905 is a clinical study titled "Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer". The purpose of this study is to examine the safety and efficacy of cirmtuzumab in combination with standard of care docetaxel in patients with metastatic castration resistant prostate cancer. Docetaxel is a taxane chemotherapy which has been shown to prolong survival in men with castration resistant...
What is the current status of trial NCT05156905?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-06-16. Estimated completion is 2024-10-01.
What interventions are being tested in trial NCT05156905?
The interventions under investigation include: Cirmtuzumab (DRUG).
Who is sponsoring clinical trial NCT05156905?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.